Magnetic Iron-Salen Paclitaxel Complex for Targeted Cancer Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-cancer agents, such as taxane-type agents, have limited effectiveness in killing triple-negative breast cancer cells, especially in the G0 and G1 phases, and cause side effects when administered to normal tissues, while drug delivery systems using carriers face challenges with molecular size and stability issues.
Innovation Solution
A magnetic iron-salen complex compound bound to paclitaxel, which can be administered without a carrier, using an external magnetic field to target and kill cancer cells in multiple phases, including G1, S, G2, and M phases, by exploiting the magnetic properties of the iron-salen complex to enhance cancer cell killing and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a carrier is used to deliver the taxane-type anti-cancer agent to affected site tissues, then the drug can be guided to the target site, but the molecular size increases and administration methods are limited
Solution Approach 1:
The patent extracts the magnetic functionality from a separate carrier system and integrates it directly into the anti-cancer agent molecule itself. The iron-salen complex is covalently bound to the taxane molecule, eliminating the need for an external carrier while retaining magnetic guidance capability. This resolves the contradiction by removing the carrier's bulk while preserving its targeting function.
Solution Approach 2:
The patent merges the drug molecule (taxane) with the magnetic carrier (iron-salen complex) into a single integrated compound. This combination allows the anti-cancer agent to possess both therapeutic function and magnetic guidance capability simultaneously, avoiding the size increase associated with traditional carrier systems while maintaining targeted delivery reliability.
2Reliability
If a carrier is used to deliver the anti-cancer agent, then the drug can be guided to affected site tissues, but the carrier and drug decompose before reaching the target site
Solution Approach 1:
By merging the drug and magnetic complex into a single integrated molecule, the patent eliminates the interface between carrier and drug that is prone to decomposition. The covalent bond between the iron-salen complex and taxane molecule ensures stable association throughout the delivery process, preventing premature dissociation while maintaining targeted delivery capability.
Solution Approach 2:
The patent removes the separate carrier entity that is susceptible to decomposition and instead incorporates magnetic functionality directly into the drug molecule. This extraction of the carrier concept while retaining its magnetic guidance function resolves the stability issue by eliminating the carrier-drug interface that leads to premature decomposition.
3Reliability
If the taxane-type anti-cancer agent is administered to normal tissues, then the drug can reach affected site tissues, but side effects such as vomiting and leukocyte decrease occur
Solution Approach 1:
The patent replaces the passive systemic distribution mechanism with active magnetic guidance. By applying an external magnetic field to guide the magnetic anti-cancer agent to the affected site, the system achieves targeted delivery without relying on random circulation through normal tissues. This substitution of magnetic guidance for passive distribution resolves the contradiction by minimizing exposure to normal tissues while maintaining effective drug delivery to the target site.
4Productivity
If the taxane-type anti-cancer agent is administered continuously, then the cancer cell killing effect is enhanced, but side effects on normal tissues increase
Solution Approach 1:
The patent replaces continuous systemic administration with magnetically-guided targeted delivery. By using an external magnetic field to concentrate the anti-cancer agent at the affected site, the system achieves continuous therapeutic effect at the target while minimizing drug exposure to normal tissues. This magnetic guidance mechanism resolves the contradiction by decoupling the duration of therapeutic effect from the duration of systemic exposure and associated side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The magnetic iron-salen complex effectively kills triple-negative breast cancer cells across multiple phases, minimizing side effects by precise targeting and heat generation, leading to enhanced cancer cell killing and improved therapeutic outcomes.
Implementation Method 1
a complex produced by making an iron-salen complex compound, which includes a central iron atom and (N, N, O, O) as a quadridentate ligand and is magnetic, the iron-salen complex compound being bound to a taxane molecule
Implementation Method 2
the killing comprises killing triple-negative breast cancer cells at an affected site tissue by applying a magnetic field to the affected site tissue upon administration of the complex and making the complex continuously indwell at the affected site tissue
Data Source
Figure 1
Figure 2
Figure 3
AI summary
[Object] An anticancer agent capable of continuously killing cancer cells in a plurality of phases is provided. [Solution] An anticancer agent contains a complex produced by making a metal-salen complex compound, which includes a central metal and (N, N, O, O) as a quadridentate ligand and is magnetic, bind to taxane molecules which are anticancerous; and the anticancer agent is to kill cancer cells regarding which phase transition of its cell cycle occurs between phases including Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis. The present invention is suited for use to kill cancer cells of breast cancer and, particularly, cancer cells of triple-negative breast cancer. The present invention is designed to make the anticancer agent contact the cancer cells in two or more continuous phases selected from a group consisting of Gap1, Synthesis, Gap2, and Mitosis and Cytokinesis and kill the cancer cells.